Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nantkwest Inc CS (NK)

Nantkwest Inc CS (NK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 150,501
  • Shares Outstanding, K 98,367
  • Annual Sales, $ 50 K
  • Annual Income, $ -96,230 K
  • 60-Month Beta 2.54
  • Price/Sales 2,951.01
  • Price/Cash Flow N/A
  • Price/Book 1.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +454,190.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.08 +34.32%
on 11/07/19
1.99 -27.29%
on 12/02/19
+0.34 (+30.36%)
since 11/05/19
3-Month
1.04 +39.13%
on 09/27/19
1.99 -27.29%
on 12/02/19
+0.20 (+15.76%)
since 09/05/19
52-Week
0.93 +55.59%
on 12/26/18
1.99 -27.29%
on 12/02/19
-0.22 (-13.35%)
since 12/04/18

Most Recent Stories

More News
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial. The...

NK : 1.48 (-3.27%)
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors

NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious...

NK : 1.48 (-3.27%)
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

--Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety

NK : 1.48 (-3.27%)
Nantkwest Inc Set to Possibly Pullback After Yesterday's Rally of 2.61%

Nantkwest Inc (NASDAQ:NK) traded in a range yesterday that spanned from a low of $1.17 to a high of $1.26. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $1.25...

NK : 1.48 (-3.27%)
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors

--NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered NK92 cells in trials: CD16 targeted haNK, CD19/CD16 targeted t-haNK and now...

NK : 1.48 (-3.27%)
Cheryl Cohen Appointed to NantKwest's Board of Directors

NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately.

NK : 1.48 (-3.27%)
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients

NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells...

NK : 1.48 (-3.27%)
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference

NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating...

NK : 1.48 (-3.27%)
Brink Biologics Announces Research License AgreementwithWorcester Polytechnic Institutefor Use of NantKwest's NK-92(R)Cells

Brink Biologics, Inc., aNantKwest, Inc. (Nasdaq:NK) affiliate who serves as exclusively-licensed distributor of NantKwest's proprietary NK-92(R) natural killer cells, offers...

NK : 1.48 (-3.27%)
Market Trends Toward New Normal in WageWorks, Maxwell Technologies, Valeritas, NantKwest, Nightstar Therapeutics PLC Sponsored ADR, and Aspen Group -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of WageWorks, Inc. (NYSE:WAGE), Maxwell...

WAGE : 51.34 (unch)
MXWL : 4.45 (-0.67%)
VLRX : 1.56 (-2.50%)
NK : 1.48 (-3.27%)
NITE : 25.41 (-0.04%)
ASPU : 6.96 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NK with:

Business Summary

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc....

See More

Key Turning Points

2nd Resistance Point 1.84
1st Resistance Point 1.68
Last Price 1.48
1st Support Level 1.39
2nd Support Level 1.26

See More

52-Week High 1.99
Fibonacci 61.8% 1.59
Last Price 1.48
Fibonacci 50% 1.46
Fibonacci 38.2% 1.33
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar